At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 12, 2026 at 08:05 ET
McKesson Corp subsidiary McKesson Medical-Surgical Top Holdings Inc. amended its April 2026 credit agreement to add a $2.25 billion senior secured Term B loan due 2032, with JPMorgan as sole lender. Proceeds will fund transaction costs and the broader spin-off/restructuring (the 'Transactions'). The facility carries an interest rate of SOFR + 2.25% (Term Benchmark) or Base Rate + 1.25% and is secured by substantially all assets of the borrower and its material US subsidiaries. This is a significant increase in subsidiary-level leverage but appears to be a planned component of the medical-surgical business separation from McKesson Corp.
- $2.25 billion incremental senior secured Term B loan added to existing credit agreement for McKesson Medical-Surgical Top Holdings Inc.
- Loan matures in 2032 (sixth anniversary of June 9, 2026 closing) and is priced at SOFR + 2.25% per annum (or Base Rate + 1.25%)
- JPMorgan Chase Bank, N.A. is the sole Amendment No. 1 Term B Lender for this tranche
- Proceeds are stated to be used to pay fees/expenses of the amendment and to fund the 'Transactions', likely including the planned spin-off of McKesson's medical-surgical business
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access